Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:EC 1.14.13.72 (methylsterol monooxygenase) inhibitor
go back to main search page
Accession:CHEBI:83316 term browser browse the term
Definition:An EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of methylsterol monooxygenase (EC 1.14.13.72).
Synonyms:related_synonym: 4,4-dimethyl-5alpha-cholest-7-en-3beta-ol,NAD(P)H:oxygen oxidoreductase (hydroxylating) inhibitor;   4,4-dimethyl-5alpha-cholest-7-en-3beta-ol,NAD(P)H:oxygen oxidoreductase (hydroxylating) inhibitors;   4,4-dimethyl-5alpha-cholest-7-en-3beta-ol,hydrogen-donor:oxygen oxidoreductase (hydroxylating) inhibitor;   4,4-dimethyl-5alpha-cholest-7-en-3beta-ol,hydrogen-donor:oxygen oxidoreductase (hydroxylating) inhibitors;   4-methylsterol oxidase inhibitor;   4-methylsterol oxidase inhibitors;   EC 1.14.13.72 (ethylsterol monooxygenase) inhibitors;   EC 1.14.13.72 inhibitor;   EC 1.14.13.72 inhibitors;   methylsterol hydroxylase inhibitor;   methylsterol hydroxylase inhibitors;   methylsterol monooxygenase (EC 1.14.13.72) inhibitors;   methylsterol monooxygenase inhibitor;   methylsterol monooxygenase inhibitors
 xref: Wikipedia:Methylsterol_monooxygenase



show annotations for term's descendants           Sort by:
 
fenhexamid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ANXA10 annexin A10 increases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of ANXA10 mRNA CTD PMID:32194361 NCBI chr 4:168,092,537...168,187,736
Ensembl chr 4:168,092,537...168,187,736
JBrowse link
G AR androgen receptor multiple interactions
affects binding
EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]
N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide binds to AR protein
CTD PMID:21310686 PMID:23436777 NCBI chr  X:67,544,021...67,730,619
Ensembl chr  X:67,544,021...67,730,619
JBrowse link
G ARG1 arginase 1 decreases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of ARG1 mRNA CTD PMID:32194361 NCBI chr 6:131,573,226...131,584,329
Ensembl chr 6:131,470,832...131,584,332
JBrowse link
G ATM ATM serine/threonine kinase increases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of ATM mRNA CTD PMID:25461557 NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,223,044...108,369,102
JBrowse link
G BAX BCL2 associated X, apoptosis regulator decreases expression
multiple interactions
EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of BAX protein
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of BAX protein]; [Fulvestrant co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of BAX protein]; Fulvestrant inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of BAX protein]
CTD PMID:33484789 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions
increases expression
decreases expression
EXP MIR21 mRNA mutant form inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of BCL2 protein]
N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of BCL2 mRNA; N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of BCL2 protein
CTD PMID:23052036 PMID:33484789 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
JBrowse link
G BIRC5 baculoviral IAP repeat containing 5 increases expression
multiple interactions
EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of BIRC5 protein
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of BIRC5 protein]; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [Fulvestrant inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of BIRC5 protein]]; Fulvestrant inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of BIRC5 protein]; Fulvestrant promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of BIRC5 protein]]
CTD PMID:33484789 NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
JBrowse link
G CASP9 caspase 9 multiple interactions EXP [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with Fulvestrant co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased cleavage of CASP9 protein CTD PMID:33484789 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CCND1 cyclin D1 multiple interactions
increases expression
decreases expression
EXP ESR1 protein affects the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of CCND1 mRNA]; Fulvestrant inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of CCND1 protein]
N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of CCND1 mRNA; N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of CCND1 protein
CTD PMID:23052036 PMID:23436777 PMID:26344002 PMID:33484789 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
JBrowse link
G CCNE1 cyclin E1 multiple interactions
increases expression
EXP [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with Fulvestrant] inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of CCNE1 protein]; Fulvestrant inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of CCNE1 protein] CTD PMID:26344002 PMID:33484789 NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312
JBrowse link
G CDC25A cell division cycle 25A increases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of CDC25A mRNA CTD PMID:25461557 NCBI chr 3:48,157,146...48,188,417
Ensembl chr 3:48,157,146...48,188,417
JBrowse link
G COL18A1 collagen type XVIII alpha 1 chain multiple interactions EXP [systhane co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide] results in decreased expression of COL18A1 mRNA CTD PMID:25461557 NCBI chr21:45,405,165...45,513,720
Ensembl chr21:45,405,165...45,513,720
JBrowse link
G CTSD cathepsin D multiple interactions
increases expression
EXP fulvestrant inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of CTSD protein] CTD PMID:26344002 NCBI chr11:1,752,755...1,763,927
Ensembl chr11:1,752,752...1,764,573
JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 decreases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of CYP1A1 mRNA CTD PMID:32194361 NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
JBrowse link
G CYP2C19 cytochrome P450 family 2 subfamily C member 19 decreases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of CYP2C19 protein CTD PMID:32194361 NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions EXP [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with pyrimethanil co-treated with Fenitrothion co-treated with triadimefon co-treated with quinoxyfen co-treated with penconazole] results in increased expression of CYP3A4 mRNA CTD PMID:25028461 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 decreases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of CYP7A1 mRNA CTD PMID:32194361 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G ESR1 estrogen receptor 1 multiple interactions
increases activity
decreases expression
EXP [fludioxonil co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with Chlorpyrifos] results in increased activity of ESR1 protein; [fludioxonil co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with propamocarb] results in increased activity of ESR1 protein; [fludioxonil co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide] results in increased activity of ESR1 protein; ESR1 protein affects the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of CCND1 mRNA]; N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide binds to and results in increased activity of ESR1 protein; N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; Tamoxifen inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased activity of ESR1 protein]
N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of ESR1 mRNA
CTD PMID:20143881 PMID:23052036 PMID:23436777 PMID:26812056 NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
JBrowse link
G ESR2 estrogen receptor 2 multiple interactions
increases expression
increases activity
EXP [fludioxonil co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with propamocarb] results in increased activity of ESR2 protein; [fludioxonil co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide] results in increased activity of ESR2 protein; N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA]
N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of ESR2 mRNA
N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased activity of ESR2 protein
CTD PMID:23436777 PMID:26812056 NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
JBrowse link
G ETS2 ETS proto-oncogene 2, transcription factor multiple interactions EXP [systhane co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide] results in decreased expression of ETS2 mRNA CTD PMID:25461557 NCBI chr21:38,805,183...38,824,955
Ensembl chr21:38,805,183...38,824,955
JBrowse link
G ITGA4 integrin subunit alpha 4 increases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of ITGA4 mRNA CTD PMID:25461557 NCBI chr 2:181,457,205...181,538,940
Ensembl chr 2:181,457,202...181,538,940
JBrowse link
G ITGAV integrin subunit alpha V increases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of ITGAV mRNA CTD PMID:25461557 NCBI chr 2:186,590,056...186,680,901
Ensembl chr 2:186,590,056...186,680,901
JBrowse link
G ITGB1 integrin subunit beta 1 multiple interactions EXP [systhane co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide] results in decreased expression of ITGB1 mRNA CTD PMID:25461557 NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792
JBrowse link
G MIR200A microRNA 200a increases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR200A mRNA CTD PMID:23052036 NCBI chr 1:1,167,863...1,167,952
Ensembl chr 1:1,167,863...1,167,952
JBrowse link
G MIR21 microRNA 21 multiple interactions
increases expression
EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA]; bicalutamide inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA]; Dactinomycin inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA]; fulvestrant inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA]; MIR21 mRNA mutant form inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of BCL2 protein]; MIR21 mRNA mutant form inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of PDCD4 protein]; wortmannin inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA] CTD PMID:23052036 NCBI chr17:59,841,266...59,841,337
Ensembl chr17:59,841,266...59,841,337
JBrowse link
G MIR22 microRNA 22 increases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR22 mRNA CTD PMID:23052036 NCBI chr17:1,713,903...1,713,987
Ensembl chr17:1,713,903...1,713,987
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions EXP [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with pyrimethanil co-treated with Fenitrothion co-treated with triadimefon co-treated with quinoxyfen co-treated with penconazole] results in increased activity of NR1I2 protein CTD PMID:25028461 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
JBrowse link
G PCNA proliferating cell nuclear antigen increases expression
multiple interactions
EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of PCNA protein
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of PCNA protein]; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [Fulvestrant inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of PCNA protein]]; Fulvestrant inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of PCNA protein]; Fulvestrant promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of PCNA protein]]
CTD PMID:33484789 NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
JBrowse link
G PDCD4 programmed cell death 4 multiple interactions
decreases expression
EXP MIR21 mRNA mutant form inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of PDCD4 protein]
N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of PDCD4 mRNA; N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of PDCD4 protein
CTD PMID:23052036 NCBI chr10:110,871,928...110,900,006
Ensembl chr10:110,871,795...110,900,006
JBrowse link
G PDGFA platelet derived growth factor subunit A increases expression
multiple interactions
EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of PDGFA mRNA
[systhane co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide] results in increased expression of PDGFA mRNA
CTD PMID:25461557 NCBI chr 7:497,258...520,700
Ensembl chr 7:497,258...520,296
JBrowse link
G PDGFB platelet derived growth factor subunit B multiple interactions EXP [systhane co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide] results in decreased expression of PDGFB mRNA CTD PMID:25461557 NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982
JBrowse link
G PGR progesterone receptor decreases expression
affects binding
increases expression
EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of PGR mRNA
N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide binds to PGR protein
N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of PGR mRNA
CTD PMID:23052036 PMID:23436777 PMID:32278787 NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813
JBrowse link
G PTEN phosphatase and tensin homolog decreases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of PTEN mRNA CTD PMID:23052036 NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 CTD PMID:26359731 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
JBrowse link
G RARB retinoic acid receptor beta multiple interactions
decreases expression
EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide promotes the reaction [Estradiol results in decreased expression of RARB mRNA]
N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in decreased expression of RARB mRNA
CTD PMID:23436777 NCBI chr 3:24,829,321...25,597,932
Ensembl chr 3:24,687,887...25,597,932
JBrowse link
G RB1 RB transcriptional corepressor 1 increases expression
multiple interactions
EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of RB1 mRNA
[systhane co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide] affects the expression of RB1 mRNA
CTD PMID:25461557 NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
JBrowse link
G S100P S100 calcium binding protein P increases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of S100P mRNA CTD PMID:32194361 NCBI chr 4:6,693,878...6,697,170
Ensembl chr 4:6,693,878...6,697,170
JBrowse link
G TIMP1 TIMP metallopeptidase inhibitor 1 increases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of TIMP1 mRNA CTD PMID:25461557 NCBI chr  X:47,582,436...47,586,789
Ensembl chr  X:47,582,408...47,586,789
JBrowse link
G TIMP3 TIMP metallopeptidase inhibitor 3 increases expression EXP N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of TIMP3 mRNA CTD PMID:25461557 NCBI chr22:32,801,705...32,863,041
Ensembl chr22:32,801,705...32,863,041
JBrowse link
G VMP1 vacuole membrane protein 1 multiple interactions
increases expression
EXP Dactinomycin inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of VMP1 mRNA] CTD PMID:23052036 NCBI chr17:59,707,654...59,842,255
Ensembl chr17:59,707,192...59,842,255
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 25408
    role 25341
      biological role 25304
        biochemical role 24700
          enzyme inhibitor 21569
            EC 1.* (oxidoreductase) inhibitor 18845
              EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor 15982
                EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor 6336
                  EC 1.14.13.72 (methylsterol monooxygenase) inhibitor 40
                    fenhexamid 40
paths to the root